Oxidative stress and inflammation are common factors that lead to the progression of chronic kidney disease (CKD) to end-stage renal disease (ESRD), and methylbardoxolone is an agonist of antioxidant and anti-inflammatory factors such nuclear factor erythroid-related factor 2. It can increase the glomerular filtration rate (GFR) of patients with CKD. Methylbardoxolone has a good effect in increasing GFR. However, because it can increase the risk of cardiovascular events and proteinuria, and fails to improve the incidence of ESRD, it ultimately failed to become a therapeutic drug for CKD. This article reviewed the effects of methylbardoxolone in clinical trials of CKD drugs caused by multiple factors, aiming to provide a reference for its application.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |